Furthermore, in the SUSTAIN-6 trial, semaglutide, another GLP-1 analogue, exacerbated the development of diabetic retinopathy more with semaglutide than with the placebo [147]. The gene discussed is GLP1R; the disease is diabetic retinopathy.